1-10 of 10
Frank J. Hsu
Close
Sort by
Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Hun Ju Lee, MD, Michael Y. Choi, MD, Tanya Siddiqi, MD, William G. Wierda, MD PhD, Jacqueline C. Barrientos, MD, Nicole Lamanna, MD, Alec Goldenberg, MD, Iris Isufi, MD, Joseph Tuscano, MD, Suki Subbiah, MD, Jean L. Koff, MD, Lori A. Leslie, MD, Gina G Chung, MD, Elizabeth K Weihe, MD, Xen Ianopulos, MD PhD, James B. Breitmeyer, MD PhD, Frank J Hsu, MD, Michael Wang, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-141917
Published: 2020
Journal Articles

Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma

Christopher R Flowers, MD MS, Carlos Panizo, MD PhD, Iris Isufi, MD, Alex F. Herrera, MD, Craig Okada, MD PhD, Elizabeth H. Cull, MD, Bela Kis, MD, Jorge M. Chaves, MD, Nancy L. Bartlett, MD, Weiyun Ai, MD PhD, Luis de la Cruz-Merino, MD PhD, Locke J. Bryan, MD, Roch Houot, MD PhD, Kim Linton, MBChB PhD, Javier Briones, MD, Ian Chau, MD, Gottfried R. von Keudell, MD PhD, Hailing Lu, PhD, Frank J Hsu, MD, Ahmad S Halwani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2892.
https://doi.org/10.1182/blood-2018-99-117932
Published: 2018
Journal Articles

Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Christopher Flowers, MD, Carlos Panizo, MD PhD, Iris Isufi, MD, Alex F. Herrera, MD, Craig Okada, MD PhD, Elizabeth H. Cull, MD, Bela Kis, MD, Jorge M. Chaves, MD, Nancy L. Bartlett, MD, Weiyun Ai, MD PhD, Luis de la Cruz-Merino, MD, Locke J. Bryan, MD, Roch Houot, MD PhD, Kim Linton, MBChB PhD, Javier Briones, MD, Ian Chau, MD, Gottfried R. von Keudell, MD PhD, Hailing Lu, PhD, Frank J Hsu, MD, Ahmad S. Halwani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2771.
https://doi.org/10.1182/blood.V130.Suppl_1.2771.2771
Published: 2017
Journal Articles

Intratumoral G100 Rescues Radiation-Induced T Cell Depletion and Has Synergistic Anti-Tumor Effect with Local Irradiation in A20 Lymphoma

Hailing Lu, MD PhD, Eric Ford, PhD, Jeffrey L Schwartz, PhD, Jessica Hewitt, Frank J Hsu, MD, Jan ter Meulen, MD, Ramesh Rengan, MD PhD
Journal: Blood
Blood (2016) 128 (22): 4166.
https://doi.org/10.1182/blood.V128.22.4166.4166
Published: 2016
Journal Articles

Intratumoral Injection of TLR4 Agonist (G100) Leads to Tumor Regression of A20 Lymphoma and Induces Abscopal Responses

Idit Sagiv-Barfi, Hailing Lu, MDPhD, Jessica Hewitt, Frank J Hsu, MD, Jan ter Meulen, MD, Ronald Levy, MD
Journal: Blood
Blood (2015) 126 (23): 820.
https://doi.org/10.1182/blood.V126.23.820.820
Published: 2015
Journal Articles

The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome

Brief Report
David C. Dale, Audrey Anna Bolyard, Merideth L. Kelley, Ernest C. Westrup, Vahagn Makaryan, Andrew Aprikyan, Brent Wood, Frank J. Hsu
Journal: Blood
Blood (2011) 118 (18): 4963–4966.
https://doi.org/10.1182/blood-2011-06-360586
Published: 2011
Journal Articles

Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia

Leslie Andritsos, MD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH, Becker Hewes, MD, Thomas J. Kipps, MD, PhD, Frank J Hsu, Jan A. Burger, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2450.
https://doi.org/10.1182/blood.V116.21.2450.2450
Published: 2010
Journal Articles

Similar 1 Year Survival of Patients Receiving Plerixafor (Mozobil*®) Plus G-CSF Versus Placebo Plus G-CSF Mobilized Autologous Grafts: Results From Two Phase 3 Randomized Trials in Patients with NHL or MM Undergoing Autologous Transplantation After Front-Line or Rescue Mobilization.

Ivana N Micallef, MD, Patrick Stiff, MD, Edward Stadtmauer, MD, Brian J. Bolwell, Sachin Marulkar, MBBS, MPH, Frank J Hsu, MD, John F. DiPersio, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 2319.
https://doi.org/10.1182/blood.V114.22.2319.2319
Published: 2009
Journal Articles

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

Clinical Trials & Observations
John M. Timmerman, Debra K. Czerwinski, Thomas A. Davis, Frank J. Hsu, Claudia Benike, Zheng Mei Hao, Behnaz Taidi, Ranjani Rajapaksa, Clemens B. Caspar, Craig Y. Okada, Adrienne van Beckhoven, Tina Marie Liles, Edgar G. Engleman, Ronald Levy
Journal: Blood
Blood (2002) 99 (5): 1517–1526.
https://doi.org/10.1182/blood.V99.5.1517
Published: 2002
Journal Articles

Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial

Frank J. Hsu, Clemens B. Caspar, Debra Czerwinski, Larry W. Kwak, Tina Marie Liles, Athanasia Syrengelas, Behnaz Taidi-Laskowski, Ronald Levy
Journal: Blood
Blood (1997) 89 (9): 3129–3135.
https://doi.org/10.1182/blood.V89.9.3129
Published: 1997